MX2014007262A - Sistema de exhibicion de anticuerpos de longitud completa para celulas eucarioticas y su uso. - Google Patents
Sistema de exhibicion de anticuerpos de longitud completa para celulas eucarioticas y su uso.Info
- Publication number
- MX2014007262A MX2014007262A MX2014007262A MX2014007262A MX2014007262A MX 2014007262 A MX2014007262 A MX 2014007262A MX 2014007262 A MX2014007262 A MX 2014007262A MX 2014007262 A MX2014007262 A MX 2014007262A MX 2014007262 A MX2014007262 A MX 2014007262A
- Authority
- MX
- Mexico
- Prior art keywords
- population
- full length
- eukaryotic cells
- length antibody
- membrane
- Prior art date
Links
- 210000003527 eukaryotic cell Anatomy 0.000 title abstract 3
- 210000004027 cell Anatomy 0.000 abstract 4
- 241000700605 Viruses Species 0.000 abstract 3
- 239000012528 membrane Substances 0.000 abstract 3
- 239000002245 particle Substances 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11195375 | 2011-12-22 | ||
| EP12179029 | 2012-08-02 | ||
| PCT/EP2012/076163 WO2013092720A1 (en) | 2011-12-22 | 2012-12-19 | Full length antibody display system for eukaryotic cells and its use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014007262A true MX2014007262A (es) | 2014-08-01 |
Family
ID=47458959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014007262A MX2014007262A (es) | 2011-12-22 | 2012-12-19 | Sistema de exhibicion de anticuerpos de longitud completa para celulas eucarioticas y su uso. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150038354A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2794662A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2015503907A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140107295A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104011080B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014013035A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2854246A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1200849A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2014007262A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2625033C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201403445YA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013092720A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10793829B2 (en) | 2010-07-26 | 2020-10-06 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
| DK2597945T3 (da) | 2010-07-26 | 2020-09-21 | Trianni Inc | Transgene dyr og fremgangsmåder til anvendelse deraf |
| US10662256B2 (en) | 2010-07-26 | 2020-05-26 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
| GB201407852D0 (en) * | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
| EP3209626A4 (en) * | 2014-10-20 | 2018-03-21 | The Scripps Research Institute | Proximity based methods for selection of binding partners |
| CN104818295A (zh) * | 2015-02-03 | 2015-08-05 | 武汉友芝友生物制药有限公司 | 制备和筛选表达双特异性抗体细胞株的方法 |
| US10813346B2 (en) | 2015-12-03 | 2020-10-27 | Trianni, Inc. | Enhanced immunoglobulin diversity |
| EP3411476B1 (en) * | 2016-02-04 | 2024-04-24 | Trianni, Inc. | Enhanced production of immunoglobulins |
| IL261713B2 (en) * | 2016-03-19 | 2023-09-01 | F1 Oncology Inc | Methods and preparations for the transfer of lymphocytes and their regulated expansion |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| WO2018060239A1 (en) | 2016-09-29 | 2018-04-05 | F. Hoffmann-La Roche Ag | Improved method for selecting polypeptide producing cells |
| WO2018071913A2 (en) * | 2016-10-14 | 2018-04-19 | Dana-Farber Cancer Institute, Inc. | Modular tetrameric bispecific antibody platform |
| GB201720351D0 (en) | 2017-12-06 | 2018-01-17 | Iontas Ltd | Selecting for developability in drug discovery |
| CN110872356B (zh) * | 2018-09-03 | 2023-06-13 | 广西慧宝源健康产业有限公司 | 双特异性抗体及其使用方法 |
| WO2020177719A1 (zh) * | 2019-03-05 | 2020-09-10 | 信达生物制药(苏州)有限公司 | 展示与分泌目的多肽的酵母展示系统及其用途 |
| WO2021057726A1 (zh) * | 2019-09-23 | 2021-04-01 | 南开大学 | 利用哺乳动物展示筛选FcγR特异性结合Fc |
| JP2023518898A (ja) * | 2020-03-27 | 2023-05-08 | ディーディーバイオ．カンパニー、リミテッド | 哺乳動物細胞の表面に二重特異性抗体を提示する方法およびベクター |
| CN113150122B (zh) * | 2021-05-19 | 2023-03-17 | 上海儒克生物科技有限公司 | 高通量全兔源单克隆抗体的制备方法 |
| IL313740A (en) * | 2021-12-23 | 2024-08-01 | Helsingin Yliopisto | A method for screening a signal peptide for efficient expression and secretion of a heterologous polypeptide in mammalian cells |
| CN119654417A (zh) | 2022-06-10 | 2025-03-18 | 富士胶片戴奥辛思生物技术英国有限公司 | 细胞的制备方法、异源多聚体蛋白质的制造方法、双特异性抗体的制造方法、载体组、哺乳动物细胞、cho细胞和细胞池的制备方法 |
| CN119574886A (zh) * | 2024-11-29 | 2025-03-07 | 苏州泓迅生物科技股份有限公司 | 一种基于动物细胞表面展示库的抗体筛选方法及应用 |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| JP4213224B2 (ja) * | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| PT994903E (pt) | 1997-06-24 | 2005-10-31 | Genentech Inc | Metodos e composicoes para glicoproteinas galactosiladas |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| EP1028751B1 (en) | 1997-10-31 | 2008-12-31 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| EP1034298B1 (en) | 1997-12-05 | 2011-11-02 | The Scripps Research Institute | Humanization of murine antibody |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING A POLYPEPTIDE |
| US20030180714A1 (en) | 1999-12-15 | 2003-09-25 | Genentech, Inc. | Shotgun scanning |
| MXPA02010011A (es) | 2000-04-11 | 2003-04-25 | Genentech Inc | Anticuerpos multivalentes y usos para los mismos. |
| US6627442B1 (en) * | 2000-08-31 | 2003-09-30 | Virxsys Corporation | Methods for stable transduction of cells with hiv-derived viral vectors |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| EP3263702A1 (en) | 2000-10-06 | 2018-01-03 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DE60126130T2 (de) | 2000-11-17 | 2007-10-18 | The University Of Rochester | In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| RU2321630C2 (ru) | 2001-08-03 | 2008-04-10 | Гликарт Биотекнолоджи АГ | Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью |
| AU2002339224B2 (en) | 2001-09-14 | 2008-10-09 | Kuros Us Llc | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
| JP4671389B2 (ja) | 2001-10-05 | 2011-04-13 | サイトス バイオテクノロジー アーゲー | アンジオテンシンペプチド−担体複合体およびその使用 |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| DE60229659D1 (de) | 2001-11-07 | 2008-12-11 | Cytos Biotechnology Ag | Antigen-raster enthaltend rankl zur behandlung von knochenerkrankungen |
| DK1443960T3 (da) | 2001-11-07 | 2009-03-23 | Cytos Biotechnology Ag | Antigen-arrays der betegner IL-5, IL-13 eller eotaxin til behandling af allergiske eosinofile sygdomme |
| HUP0402164A3 (en) * | 2001-11-16 | 2010-01-28 | Biogen Idec Inc | Polycistronic expression of antibodies |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| CN1429916A (zh) * | 2001-12-30 | 2003-07-16 | 韩泽广 | 规模化原核和真核细胞体内抗体和抗原文库构建及筛选 |
| US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| US7749753B2 (en) | 2002-04-09 | 2010-07-06 | Kyowa Hakko Kirin Co., Ltd | Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost |
| WO2003084570A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM |
| US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
| PL373256A1 (en) | 2002-04-09 | 2005-08-22 | Kyowa Hakko Kogyo Co, Ltd. | Cells with modified genome |
| EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20050112095A1 (en) * | 2002-07-09 | 2005-05-26 | Tsu-An Hsu | Internal ribosome entry sites for recombinant protein expression |
| EP2351770A1 (en) | 2002-07-17 | 2011-08-03 | Cytos Biotechnology AG | Molecular antigen arrays using a virus like particle derived from the ap205 coat protein |
| IN2008CN05409A (cg-RX-API-DMAC7.html) | 2002-07-18 | 2015-10-02 | Cytos Biotechnology Ag | |
| RU2325202C2 (ru) | 2002-07-19 | 2008-05-27 | Цитос Байотекнолоджи Аг | Конъюгаты грелин-носитель |
| ATE506964T1 (de) | 2002-07-19 | 2011-05-15 | Cytos Biotechnology Ag | Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays |
| WO2004056312A2 (en) | 2002-12-16 | 2004-07-08 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| EP1585767A2 (en) | 2003-01-16 | 2005-10-19 | Genentech, Inc. | Synthetic antibody phage libraries |
| NZ542353A (en) * | 2003-03-20 | 2008-07-31 | Alphavax Inc | Improved alphavirus replicons and helper constructs |
| MXPA05009289A (es) | 2003-03-26 | 2005-10-18 | Cytos Biotechnology Ag | Conjugados de particulas tipo virus del analogo del peptido melan-a. |
| US20060286035A1 (en) | 2003-04-29 | 2006-12-21 | Cytos Biotechnology Ag | Methods and compositions for modulating the interaction between adiponectin and its receptor |
| EP1623229A2 (en) | 2003-05-15 | 2006-02-08 | Cytos Biotechnology AG | Selection of b cells with specificity of interest: method of preparation and use |
| EP1639009B1 (en) * | 2003-05-30 | 2013-02-27 | Merus B.V. | Fab library for the preparation of a mixture of antibodies |
| CN1289668C (zh) * | 2003-06-12 | 2006-12-13 | 北京安波特基因工程技术有限公司 | 一种用于抗体改形的体外分子定向进化方法 |
| ATE494910T1 (de) | 2003-07-10 | 2011-01-15 | Cytos Biotechnology Ag | Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort |
| CN103205436B (zh) | 2003-07-15 | 2016-05-25 | 人类多克隆治疗公司 | 人源化免疫球蛋白基因座 |
| CA2542046A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
| WO2005035778A1 (ja) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法 |
| RS55723B1 (sr) | 2003-11-05 | 2017-07-31 | Roche Glycart Ag | Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| WO2005068639A2 (en) | 2004-01-20 | 2005-07-28 | Cytos Biotechnology Ag | Particle-induced ghrelin immune response |
| BRPI0508761A (pt) | 2004-03-31 | 2007-08-14 | Genentech Inc | anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| WO2005108425A1 (en) | 2004-05-10 | 2005-11-17 | Cytos Biotechnology Ag | Il-23 p19 antigen array and uses thereof |
| US20080019991A1 (en) | 2004-06-02 | 2008-01-24 | Cytos Biotechnology Ag | Carrier Conjugates Of Tnf-Peptides |
| MXPA06013854A (es) | 2004-06-02 | 2007-03-02 | Cytos Biotechnology Ag | Usos medicos de conjugados portadores de peptidos del factor de necrosis tumoral, no humanos. |
| AU2005281743A1 (en) | 2004-08-04 | 2006-03-16 | Cytos Biotechnology Ag | Carrier conjugates of GnRH-peptides |
| NZ554387A (en) | 2004-09-21 | 2009-09-25 | Cytos Biotechnology Ag | Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide |
| BRPI0516775A (pt) | 2004-10-25 | 2008-09-23 | Cytos Biotechnology Ag | ensaios de polipeptìdeo de antìgeno de inibidor gástrico (gip) e seus usos |
| RU2007126553A (ru) | 2004-12-13 | 2009-01-20 | Цитос Биотехнологи Аг (Ch) | Упорядоченные ряды антигенов ил-15 и их применение |
| US7767212B2 (en) | 2005-03-18 | 2010-08-03 | Cytos Biotechnology Ag | CAT allergen conjugates and uses thereof |
| KR20080073293A (ko) * | 2005-10-14 | 2008-08-08 | 메디뮨 엘엘씨 | 항체 라이브러리의 세포 디스플레이 |
| ES2577292T3 (es) | 2005-11-07 | 2016-07-14 | Genentech, Inc. | Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso |
| EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| US7846724B2 (en) * | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| WO2007134050A2 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| EP1975239A1 (en) * | 2006-09-27 | 2008-10-01 | Bundesrepublik Deutschland, letztvertreten durch den Präsidenten des Paul-Ehrlich-Instituts Prof. Dr. Johannes Löwer | Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high-throughput screening |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
| EP2098536A1 (en) * | 2008-03-05 | 2009-09-09 | 4-Antibody AG | Isolation and identification of antigen- or ligand-specific binding proteins |
| CN102369215B (zh) | 2009-04-02 | 2015-01-21 | 罗切格利卡特公司 | 包含全长抗体和单链Fab片段的多特异性抗体 |
| ES2537100T3 (es) | 2009-04-07 | 2015-06-02 | Roche Glycart Ag | Anticuerpos biespecíficos trivalentes |
| BRPI1007602A2 (pt) | 2009-05-27 | 2016-02-16 | Hoffmann La Roche | "anticorpo tri ou tetraespecífico, método para preparação de um anticorpo triespecífico ou tetraespecífico, célula hospedeira, composição, composição farmacêutica e método para o tratamento de um paciente com necessidade de terapia" |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| PL2606064T3 (pl) * | 2010-08-16 | 2015-07-31 | Novimmune Sa | Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał |
| CA2791109C (en) * | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
-
2012
- 2012-12-19 WO PCT/EP2012/076163 patent/WO2013092720A1/en not_active Ceased
- 2012-12-19 MX MX2014007262A patent/MX2014007262A/es unknown
- 2012-12-19 EP EP12808373.0A patent/EP2794662A1/en not_active Withdrawn
- 2012-12-19 CN CN201280063751.7A patent/CN104011080B/zh not_active Expired - Fee Related
- 2012-12-19 HK HK15101214.1A patent/HK1200849A1/xx unknown
- 2012-12-19 SG SG11201403445YA patent/SG11201403445YA/en unknown
- 2012-12-19 RU RU2014129736A patent/RU2625033C2/ru not_active IP Right Cessation
- 2012-12-19 KR KR1020147016981A patent/KR20140107295A/ko not_active Ceased
- 2012-12-19 BR BR112014013035A patent/BR112014013035A2/pt not_active IP Right Cessation
- 2012-12-19 JP JP2014547977A patent/JP2015503907A/ja not_active Ceased
- 2012-12-19 CA CA2854246A patent/CA2854246A1/en not_active Abandoned
-
2014
- 2014-06-20 US US14/310,309 patent/US20150038354A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201403445YA (en) | 2014-07-30 |
| RU2625033C2 (ru) | 2017-07-11 |
| BR112014013035A2 (pt) | 2018-10-09 |
| EP2794662A1 (en) | 2014-10-29 |
| US20150038354A1 (en) | 2015-02-05 |
| RU2014129736A (ru) | 2016-02-20 |
| CA2854246A1 (en) | 2013-06-27 |
| WO2013092720A1 (en) | 2013-06-27 |
| CN104011080B (zh) | 2017-10-20 |
| HK1200849A1 (en) | 2015-08-14 |
| JP2015503907A (ja) | 2015-02-05 |
| KR20140107295A (ko) | 2014-09-04 |
| CN104011080A (zh) | 2014-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014007262A (es) | Sistema de exhibicion de anticuerpos de longitud completa para celulas eucarioticas y su uso. | |
| PH12020551028A1 (en) | Methods, kits and apparatus for expanding a population of cells | |
| WO2012092376A3 (en) | Comprehensive monoclonal antibody generation | |
| MX2024006992A (es) | Anticuerpos contra ligando 1 de muerte programada. | |
| AR091116A1 (es) | Anticuerpos biespecificos y sus metodos de uso | |
| MX2018003820A (es) | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador. | |
| GB201108236D0 (en) | Method | |
| PH12017500596A1 (en) | Car expression vector and car-expressing t cells | |
| AU2012222463A8 (en) | Cea antibodies | |
| EP4303229A3 (en) | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules | |
| EP4477668A3 (en) | Heterodimeric antibody fc-containing proteins and methods for production thereof | |
| WO2014011993A3 (en) | Epitope spreading associated with car t-cells | |
| NZ611600A (en) | Means and methods for producing high affinity antibodies | |
| CR20130669A (es) | Molèculas biespecìficas de uniòn a antìgeno activadoras de cèlulas t | |
| PH12014501758B1 (en) | Cd47 antibodies and methods of use thereof | |
| EP3467101A3 (en) | Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells | |
| BR112013018311A2 (pt) | sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada. | |
| UA111340C2 (uk) | Антитіло, яке специфічно зв'язується з tnf-альфа людини | |
| IN2014CN02113A (cg-RX-API-DMAC7.html) | ||
| WO2014146074A3 (en) | Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens | |
| BR112014014239A2 (pt) | método, método para produzir um anticorpo, vetor de expressão, método para seleção de uma célula de mamífero recombinante, uso de um vetor de expressão, plasmídeo de expressão, um aspecto, método para a seleção de célula eucarionte que expressa um anticorpo, plasmídeo de expressão, uso de um plasmídeo de expressão e plasmídeo de expressão ou o uso ou o método | |
| EP4527921A3 (en) | Renal cell populations and uses thereof | |
| MX366112B (es) | Medio de cultivo celular y metodos de produccion de anticuerpos. | |
| NZ628251A (en) | Cd8+t-cell subsets as markers for prediction of delayed fracture healing | |
| WO2012178150A3 (en) | Methods for developing antigen-specific antibody-producing cell lines and monoclonal antibodies |